32 Results

People

  1. Palomba
    Palomba
  2. Zelenetz
    Zelenetz
  3. Intlekofer
    Intlekofer
  4. Hamlin
    Hamlin
  5. Noy
    Noy
  6. Horwitz
    Horwitz
  7. Moskowitz
    Moskowitz
  8. Kumar
    Kumar
  9. Caron
    Caron
  10. Vardhana
    Vardhana

Groups

  1. Center for Hematologic Malignancies (32)
  2. Department of Medicine (32)
  3. GSK Faculty (32)
  4. Hematologic Malignancies Research (32)
  5. Hematologic Malignancies, Division of (32)
  6. Lymphoma (32)
  7. Human Oncology and Pathogenesis Program (31)
  8. Population Sciences Research Program (28)
  9. Sloan Kettering Institute Postdocs (22)
  10. Survivorship Research (22)
  1. "Hematologic Malignancies Research"
  2. "Center for Hematologic Malignancies"
  3. "Maria Palomba"
  4. "Andrew Zelenetz"
Formats
  1. Meeting Abstract (27)
  2. Journal Article (5)
Groups
  1. Center for Hematologic Malignancies (32)
  2. Department of Medicine (32)
  3. GSK Faculty (32)
  4. Hematologic Malignancies Research (32)
  5. Hematologic Malignancies, Division of (32)
  6. Lymphoma (32)

More Groups

People
  1. Andrew Zelenetz (32)
  2. Maria Palomba (32)
  3. Andrew Intlekofer (31)
  4. Ariela Noy (28)
  5. Paul Hamlin (28)
  6. Alison Moskowitz (27)

More People

Years
  1. 2023 (12)
  2. 2022 (3)
  3. 2021 (1)
  4. 2020 (3)
  5. 2019 (2)
  6. 2018 (1)

More Years

Publications
  1. Blood (22)
  2. Hematological Oncology (3)
  3. Blood Advances (2)
  4. Journal of Clinical Oncology (2)
  5. Blood Cancer Journal (1)
  6. Laboratory Investigation (1)

More Publications

Publishers
  1. American Society of Hematology (24)
  2. Wiley Blackwell (3)
  3. American Society of Clinical Oncology (2)
  4. Nature Publishing Group (2)
  5. Nature Research (1)

Results (32)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Responses and outcomes after second-line therapy in transplant-eligible patients with DLBCL relapse over 1 year after first-line therapy
    Meeting Abstract

    Qualls, D. A.; Shah, G. L.; Shouval, R.; Caron, P.; David, K. A.; Falchi, L.; Ghione, P.; Hamlin, P. A.; Horwitz, S. M.; Intlekofer, A. M.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Impact of early histological transformation on survival in patients with follicular lymphoma
    Journal Article

    Luttwak, E.; Qiu, A.; Okwali, M.; Rivas-Delgado, A.; Isgor, I.; Boardman, A. P.; Caron, P.; David, K. A.; Falchi, L.; Ghione, P.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Infectious complications in patients with relapsed or refractory (R/R) Non-Hodgkin's lymphoma (NHL) treated with the anti-CD20xCD3 bispecific antibody (BsAb) mosunetuzumab
    Meeting Abstract

    Shahid, Z.; Okwali, M.; Joseph, A.; Seo, S. K.; Lue, J. K.; Boardman, A. P.; Caron, P.; David, K. A.; Epstein-Peterson, Z. D.; Ghione, P.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Clinical characteristics and outcomes of limited stage high grade B-cell lymphoma with MYC/BCL2 and/or BCL6 rearrangements: A single center experience
    Meeting Abstract

    Lue, J. K.; Luttwak, E.; Caron, P.; Boardman, A. P.; David, K. A.; Rivas-Delgado, A.; Epstein-Peterson, Z. D.; Falchi, L.; Ghione, P.; Hamlin, P. A.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Brentuximab vedotin-based regimens for older patients with newly diagnosed classical Hodgkin lymphoma -Real world experience
    Meeting Abstract

    Luttwak, E.; Ganesan, N.; Boardman, A. P.; Caron, P.; David, K. A.; Rivas-Delgado, A.; Falchi, L.; Ghione, P.; Hamlin, P. A.; Horwitz, S. M.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Predicting toxicities in older adults with non-Hodgkin lymphoma (NHL) receiving systemic chemotherapy: A prospective geriatric assessment (GA) study
    Meeting Abstract

    Torka, P.; Drill, E.; Ganesan, N.; Oliveros, M.; Boardman, A. P.; Caron, P.; David, K. A.; Epstein-Peterson, Z. D.; Falchi, L.; Ghione, P.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Distinct patterns of CD4+and CD8+ T-cell clonal expansion enable broad clinical responses to pembrolizumab + GVD in patients with relapsed Hodgkin lymphoma
    Meeting Abstract

    Wills, B.; Rahman, J.; Ganesan, N.; Shah, G. L.; Noy, A.; Schoder, H.; Yahalom, J.; Kumar, A.; Falchi, L.; Hamlin, P. A.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Real-life experience with lenalidomide plus anti-CD20 antibodies for the treatment of patients (pts) with relapsed/refractory (R/R) indolent non-Hodgkin lymphoma (iNHL)
    Meeting Abstract

    Cassanello, G.; Rivas-Delgado, A.; Luna De Abia, A.; Corona, M.; Luttwak, E.; Okwali, M.; Isgor, I.; Galera, P.; Boardman, A. P.; Caron, P.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • TP53 mutations identify high-risk events for peripheral T-cell lymphoma treated with CHOP-based chemotherapy
    Journal Article

    Johnson, W. T.; Ganesan, N.; Epstein-Peterson, Z. D.; Moskowitz, A. J.; Stuver, R. N.; Maccaro, C. R.; Galasso, N.; Chang, T.; Khan, N.; Aypar, U.; more...
    Blood Advances (2023)

    Fulltext@MSK | Save
  • Retrospective characterization of nodal marginal zone lymphoma
    Journal Article

    Stuver, R.; Drill, E.; Qualls, D.; Okwali, M.; Batlevi, C. L.; Caron, P. C.; Dogan, A.; Epstein-Peterson, Z. D.; Falchi, L.; Hamlin, P. A.; more...
    Blood Advances (2023)

    Fulltext@MSK | Save